AMNEAL PHARMACEUTICALS, INC. Proceeds from Issuance of Debt
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Proceeds from Issuance of Debt of $134.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2026-06-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2026-03-31 was $134.67M.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2025-06-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for the quarter ending 2025-03-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2025 was $2.69B.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2023 was $217.73M.
- AMNEAL PHARMACEUTICALS, INC. proceeds from issuance of debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $134.67M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $134.67M 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | $2.69B 10-K · filed 2026-02-27 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | ||
| 2023-12-31 | $217.73M 10-K · filed 2026-02-27 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |